Table 4.
Item | Experimental group (n = 66) | Control group (n = 40) | t | P |
---|---|---|---|---|
BGP (ng/mL) | ||||
Before treatment | 3.39 ± 0.58 | 3.42 ± 0.61 | 0.253 | 0.801 |
After treatment | 5.78 ± 1.26ab | 4.13 ± 0.94a | 7.157 | 0.000 |
OPG (pg/mL) | ||||
Before treatment | 118.42 ± 12.37 | 120.51 ± 12.64 | 0.836 | 0.405 |
After treatment | 232.85 ± 24.19ab | 163.79 ± 17.38a | 15.747 | 0.000 |
CTX-II | ||||
Before treatment | 2.36 ± 0.27 | 2.41 ± 0.29 | 0.899 | 0.371 |
After treatment | 0.94 ± 0.08ab | 1.62 ± 0.18a | 18.569 | 0.000 |
COMP | ||||
Before treatment | 4.85 ± 0.62 | 4.90 ± 0.67 | 0.390 | 0.697 |
After treatment | 2.59 ± 0.31ab | 3.46 ± 0.48a | 11.345 | 0.000 |
RANKL | ||||
Before treatment | 84.73 ± 9.69 | 83.82 ± 9.44 | 0.473 | 0.637 |
After treatment | 54.38 ± 5.77ab | 72.95 ± 7.51a | 14.307 | 0.000 |
Compared with before treatment, aP < 0.05; compared with control group, bP < 0.05. BGP bone gamma-carboxy glutamic acid-containing protein, COMP cartilage oligomeric matrix protein, CTX-II crosslinked c-telopeptide of type II collagen, OPG orthopantomography, RANKL cell nuclear factor κB acceptor activating factor ligand